Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.38 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 7/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 6/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 3/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.34 |
| ▸ | RARB | P10826 | 1/20 | 0.34 |
| ▸ | THRA | P10827 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | ACACA | Q13085 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19796408 | 1.00 | CYP4F2 (0.38) | CYP4F2CYP4A11FFAR4FFAR1ALOX5 | |
| SCHEMBL19796414 | 0.93 | CYP4A11 (0.38) | CYP4F2CYP4A11FFAR4FFAR1ALOX5 | |
| SCHEMBL19796343 | 0.93 | CYP4A11 (0.38) | CYP4F2CYP4A11FFAR4FFAR1ALOX5 | |
| SCHEMBL19796406 | 0.92 | ALOX5 (0.36) | FFAR4FFAR1ALOX5MCL1THRB | |
| SCHEMBL19796316 | 0.92 | FFAR4 (0.36) | FFAR4FFAR1ALOX5MCL1THRB | |
| SCHEMBL19796411 | 0.89 | THRB (0.38) | CYP4F2CYP4A11ALOX5MCL1THRB | |
| SCHEMBL19796332 | 0.89 | THRB (0.38) | CYP4F2CYP4A11ALOX5MCL1THRB | |
| SCHEMBL19804104 | 0.89 | FFAR4 (0.43) | CYP4F2CYP4A11FFAR4FFAR1 | |
| SCHEMBL19796371 | 0.89 | GABRA1 (0.35) | FFAR4FFAR1ALOX5MCL1THRB | |
| SCHEMBL19796437 | 0.89 | RARB (0.38) | FFAR4FFAR1ALOX5MCL1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180023001-A1 | COMPOUND HAVING POLYMERIZABLE GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-01-25 | — | — | US | disclosed |
| US-20180023001-A1 | COMPOUND HAVING POLYMERIZABLE GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180023001-A1 | COMPOUND HAVING POLYMERIZABLE GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | SP1, C1S, AP3D1 | CYP4F2 2577/4885CYP4A11 1991/4885FFAR4 1715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.